Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transport Pharmaceuticals Device/Drug Combo For Herpes To Launch In 2007

This article was originally published in The Gray Sheet

Executive Summary

Transport Pharmaceuticals expects to file a 510(k) by early 2007 for a device/drug combination system that treats oral herpes in a single, 10-minute application

You may also be interested in...



Glaxo Licensing Deal Signals Confidence In Electrical Drug Delivery Treatment

Transport Pharmaceuticals intends to launch a 600-patient, Phase III study of its iontophoretic drug delivery device the week of March 1 to support European market go-ahead by early 2006

India Regulatory Diary: Marketers Co-Accountable For Lapses In Manufacturing Quality

New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.

UsernamePublicRestriction

Register

MT021250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel